Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 2/20 | 0.36 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ULK1 | O75385 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782940 | 0.86 | ULK1 (0.41) | EPHX2LMNATP53MAPK1NTSR1 | |
| SCHEMBL3770391 | 0.75 | RIPK1 (0.38) | P2RX3P2RX7CD38 | |
| SCHEMBL3776909 | 0.72 | SMYD3 (0.42) | MAPK1SMN1; SMN2NPSR1ALDH1A1ULK1 | |
| SCHEMBL10011414 | 0.72 | KMT2A (0.40) | KMT2AALDH1A1P2RX7CD38 | |
| SCHEMBL3773575 | 0.65 | KCNJ6 (0.37) | KMT2ASMN1; SMN2ALDH1A1TSHRP2RX7 | |
| SCHEMBL10009094 | 0.65 | GALR2 (0.41) | CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10010359 | 0.64 | P2RX7 (0.40) | MAPK1KMT2AALDH1A1P2RX7 | |
| SCHEMBL3768259 | 0.63 | LMNA (0.30) | LMNATP53 | |
| SCHEMBL3428599 | 0.63 | LMNA (0.30) | LMNATP53 | |
| SCHEMBL3781273 | 0.63 | CD38 (0.38) | EPHX2ALDH1A1TSHRRBP4TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778974-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8778974-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| EP-2257535-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-06 | — | — | EP | disclosed |
| EP-2257535-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-06 | — | — | EP | disclosed |
| CN-102066343-A | Trisubstituted 1,2, 4-triazoles as nicotinic acetylcholine receptor modulators | JANSSEN PHARMACEUTICA NV | 2011-05-18 | — | — | CN | disclosed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNE | EPHX2 3348/4885GRIN2B 256/4885LMNA 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.